Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.
The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.
The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.
Camp4 Therapeutics Corp director Michael F. MacLean filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes an insider. This filing lists him as a director but does not report any buy or sell transactions in the company’s securities.
CAMP4 Therapeutics Corporation announced that its Board of Directors has appointed Michael MacLean as a Class III director, effective April 1, 2026, and expanded the Board from eight to nine members. He will also join the Audit Committee and Compensation Committee.
MacLean brings more than 35 years of financial leadership in biotechnology and life sciences, including serving as Chief Financial Officer of Avidity Biosciences through its IPO and subsequent acquisition by Novartis, and prior senior roles at Akcea Therapeutics, PureTech Health, and Biogen. Under an amended non-employee director compensation policy, he will receive an option to purchase 56,000 shares of CAMP4 common stock, vesting in monthly installments over three years, plus standard cash retainers and the company’s standard director indemnification agreement.
Enavate Sciences entities filed Amendment No. 3 to report that they beneficially own 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class based on 51,919,321 shares outstanding as of March 4, 2026. Everest LP holds the shares directly, and Enavate Sciences GP, LLC, as general partner, shares voting and investment power. The reporting persons state they ceased to be beneficial owners of more than five percent of the common stock on March 9, 2026. In the prior sixty days, Everest LP sold multiple blocks of shares in open-market trades, including 91,699 shares on March 9, 2026 at a weighted average price of $6.69 per share and 99,639 shares on March 10, 2026 at a weighted average price of $5.83 per share.
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on RNA-targeting antisense oligonucleotides that upregulate gene expression for genetic diseases. Its proprietary RAP Platform maps regulatory RNAs to design ASOs that increase protein production in a gene-specific way, with an emphasis on central nervous system disorders.
The lead candidate, CMP-002, targets SYNGAP1-related developmental and epileptic encephalopathy. In preclinical models, CMP-002 restored SYNGAP protein toward normal levels, improved behavioral deficits in haploinsufficient mice, and increased SYNGAP protein across disease-relevant brain regions in cynomolgus monkeys. GLP toxicology studies are underway to support a planned global Phase 1/2 trial in SYNGAP1 as early as the second half of 2026.
CAMP4’s second candidate, CMP-001, aims to treat urea cycle disorders by amplifying CPS1 expression. A Phase 1 trial in healthy volunteers showed a favorable safety and pharmacokinetic profile, but further internal investment has been paused while the company seeks partners. In December 2025, CAMP4 signed a research, collaboration and license agreement with GSK, receiving a $17.5 million upfront payment and eligibility for up to $440 million in milestones plus tiered royalties on future net sales.
The company highlights extensive risk factors, including recurring losses, the need for substantial additional capital, heavy reliance on CMP-002, manufacturing and regulatory dependencies, competition from other gene-modulating and antisense companies, potential challenges maintaining Nasdaq listing standards, and significant stock price volatility. As of June 30, 2025, non-affiliate market value of common stock was approximately $14.6 million, and as of March 4, 2026, there were 51,919,321 common shares outstanding.
CAMP4 Therapeutics reported full-year 2025 results and highlighted major strategic and financing milestones. Cash and cash equivalents rose to $109.5 million as of December 31, 2025, up from $64.0 million a year earlier, and the company believes this will fund planned activities into 2028.
Research and collaboration revenue increased to $3.5 million, while R&D expenses were $38.2 million and G&A expenses were $17.4 million. Net loss widened to $80.4 million, mainly due to a $29.8 million non-cash loss from a derivative tranche liability tied to a private placement. CAMP4 entered a strategic collaboration with GSK, receiving a $17.5 million upfront payment and potential milestones up to $440 million plus tiered royalties, and completed equity financings totaling $80 million in gross proceeds with potential for an additional $50 million. The company advanced its lead SYNGAP1 program CMP-002 toward a planned global Phase 1/2 trial as early as the second half of 2026 and paused further internal investment in CMP-001 while exploring partnerships.
Camp4 Therapeutics Corp received an amended Schedule 13G/A from investment entities affiliated with Vivo Opportunity, reporting significant passive ownership stakes in its common stock. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each beneficially own 3,856,991 shares, representing 7.4% of Camp4’s common stock based on 51,880,185 shares outstanding as of December 18, 2025. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each beneficially own 389,577 shares, or 0.8% of the same share base. The filing states that these securities are not held for the purpose of changing or influencing control of Camp4, but rather as passive investments.
FMR LLC and Abigail P. Johnson report a significant ownership stake in CAMP4 Therapeutics Corporation. As of the event date, they beneficially own 4,918,243 shares of CAMP4 common stock, representing 9.5% of the outstanding class.
FMR LLC has sole voting power over 4,916,914 shares and sole dispositive power over 4,918,243 shares, while Abigail P. Johnson is reported with sole dispositive power over the same 4,918,243 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.